Mesoblast Limited: First Three Children to Commence Treatment With Ryoncil
Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has entered into the Medicaid ...
Physician's Weekly1d
Molecular Pathways in Bone Marrow Stem Cell Senescence
The following is a summary of “A Novel Molecular Regulatory Network in Bone Marrow Mesenchymal Stem Cells for Age-Related Osteoporosis,” published in the March 2025 issue of Clinical Endocrinology by ...
First Three Children to Commence Treatment With Ryoncil®
Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...
EurekAlert!1d
New method creates 854x more mitochondria, offering hope for cartilage regeneration
Scientists have unveiled a revolutionary method for mass-producing high-quality human mitochondria, potentially transforming ...
eLife3d
Compositional editing of extracellular matrices by CRISPR/Cas9 engineering of human mesenchymal stem cell lines
Human extracellular matrices can be edited in their composition using the CRISPR/Cas9 system, leading to materials exhibiting tailored regenerative capacities.
The Manila Times4d
BioRestorative Therapies Reports 2024 Financial Results and Provides Business Update
MELVILLE, N.Y., March 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative”, "BRTX” or the "Company”) ...
Ryoncil® is Now Available for Purchase in the United States
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Ryoncil ® (remestemcel-L) the first mesenchymal stromal cell ...